Movement Alert｜West Pharmaceutical Intraday Rise 5.18% in Regular Trading, Q3 Earnings Beat and 2026 Outlook Raised

Market Focus10-29

On October 29, West Pharmaceutical rose 5.18% in Regular Trading, trading at $428.4/share, with turnover of $19.86 million.

The move followed a quarterly report that exceeded expectations and an increase in full-year guidance. West Pharmaceutical reported Q3 adjusted EPS of $2.66, up from $1.96 a year earlier and above consensus near $2.19 to $2.20, while net sales rose to $874.5 million from $804.6 million, also ahead of expectations around $825.7 million to $827.1 million.

The company also lifted its 2026 outlook, guiding adjusted EPS to $9.38-$9.48 versus prior guidance of $8.85-$9.05, and projecting annual sales of $3.41 billion-$3.42 billion versus its prior $3.345 billion-$3.380 billion range. The updated sales outlook is also above the $3.38 billion consensus, reinforcing the earnings-driven nature of the stock’s advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment